[144] Amneal Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Insider sale notice for Amneal Pharmaceuticals (AMRX). The Form 144 reports a proposed sale of 219,159 common shares with an aggregate market value of $2,057,903.01 to be sold on or about 08/15/2025 on NASDAQ. The filing shows the securities were acquired through RSU vesting on three dates in March 2024 totaling 219,159 shares. The document also discloses recent completed sales by Anastasios Konidaris: 161,635 shares sold on 08/13/2025 for gross proceeds of $1,489,993.93 and 119,206 shares sold on 08/14/2025 for gross proceeds of $1,108,993.36. The filer certifies they are not aware of undisclosed material adverse information about the issuer.

Positive

• None.

Negative

• Insider selling of material size: consecutive sales totaling 280,841 shares for ~$2.60M in gross proceeds are disclosed
• Planned additional sale: a proposed sale of 219,159 shares (~$2.06M) scheduled on or about 08/15/2025

Insights

Securities Analyst

TL;DR: Significant insider share dispositions are disclosed, totaling hundreds of thousands of shares and multi‑million dollar proceeds.

The filing shows a proposed sale of 219,159 shares (market value ~$2.06M) and recent completed sales by the named seller totaling 280,841 shares for about $2.60M in gross proceeds. These are sourced from RSU vesting in March 2024 rather than open‑market purchases, indicating the shares originated from compensation. For investors, the key facts are scale and timing: concentrated insider selling over consecutive days and an additional planned sale. The filing contains no commentary on use of proceeds or any undisclosed material information.

Corporate Governance Expert

TL;DR: The Form 144 documents routine disposition of vested RSUs but signals material insider liquidity events.

The notice documents that vested RSUs (dates: 03/01/2024, 03/03/2024, 03/12/2024) underpin the securities being sold. The seller attests to lacking any undisclosed material adverse information, and the form references sales aggregated under Rule 144. From a governance perspective, this is a required disclosure of insider liquidity rather than an operational disclosure; it does not itself indicate wrongdoing but is material for share‑supply considerations. No additional governance items or trading plans are included in the filing text provided.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab Corp. 3000 Schwab Way Westlake TX 76262	219159	2057903.01	314079309	08/15/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/01/2024	RSU Vesting	Issuer			42754	03/01/2024	N/A
Common	03/03/2024	RSU Vesting	Issuer			119688	03/03/2024	N/A
Common	03/12/2024	RSU Vesting	Issuer			56717	03/12/2024	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Anastasios Konidaris 400 CROSSING BOULEVARD, 3RD FLOOR, BRIDGEWATER NJ 08807	Common	08/13/2025	161635	1489993.93
Anastasios Konidaris 400 CROSSING BOULEVARD, 3RD FLOOR,, BRIDGEWATER NJ 08807	Common	08/14/2025	119206	1108993.36

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the AMRX Form 144 disclose about the number of shares to be sold?

The notice reports a proposed sale of 219,159 common shares with an aggregate market value of $2,057,903.01.

Who completed recent sales and how many shares were sold?

Anastasios Konidaris sold 161,635 shares on 08/13/2025 and 119,206 shares on 08/14/2025.

What were the gross proceeds from the recent insider sales?

Gross proceeds reported were $1,489,993.93 for the 08/13/2025 sale and $1,108,993.36 for the 08/14/2025 sale.

How were the securities being sold originally acquired?

All securities listed were acquired via RSU vesting on 03/01/2024, 03/03/2024, and 03/12/2024.

On which exchange is the proposed sale to occur?

The filing indicates the proposed sale will occur on NASDAQ.